Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Editorial
Media & News
Original Article
Review Article
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Editorial
Media & News
Original Article
Review Article
View/Download PDF

Translate this page into:

Original Article
1 (
2
); 74-81
doi:
10.25259/STN_18_2025

Ninhydrin-Mediated Spectrophotometric Assay for the Simultaneous Analysis of Pregabalin and Duloxetine in Pharmaceutical Mixtures

Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt
Department of pharmaceutical chemistry, Badr University in Cairo, Badr City, Egypt
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Egypt
Department of Chemistry, School of Life and Medical Sciences, University of Hertfordshire Hosted By Global Academic Foundation, New Capital, Garden City, Cairo, Egypt.
Author image

* Corresponding author: Dr. Ali Mohamed Waseem, Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Egypt. aly.waseem@buc.edu.eg

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Abdallah FF, Waseem AM, Yehia AM, Farid NF. Ninhydrin-Mediated Spectrophotometric Assay for the Simultaneous Analysis of Pregabalin and Duloxetine in Pharmaceutical Mixtures. Sci Technol Nex 2025;1:74-0. doi: 10.25259/STN_18_2025

Abstract

Objective

To develop and validate a novel ultraviolet (UV)-Vis spectrophotometric method for the simultaneous determination of pregabalin (PG) and duloxetine (DL), addressing PG’s non-chromophoric nature through selective derivatisation and ensuring a sustainable, cost-effective approach suitable for routine quality control.

Material and Methods

PG was derivatised with ninhydrin in ethanol at 100°C for 5 minutes, forming a stable Ruhemann’s purple complex measured at 580 nm. DL, possessing a native naphthalene chromophore, was directly quantified at 230 nm. The distinct wavelengths eliminated mutual interference. Method validation was performed according to international council for harmonisation(ICH) Q2(R1) guidelines, assessing linearity, accuracy, precision, sensitivity, and specificity. Sustainability was evaluated using AGREE, GAPI, NEMI, Eco-scale, and BAGI tools.

Results

The method demonstrated excellent linearity (r2 ≥ 0.9996), high accuracy (mean recovery: 100.57% for PG, 100.58% for DL), and precision (%RSD < 1.2%). Sensitivity was confirmed by low limits of detection (0.549 µg/mL for PG, 0.243 µg/mL for DL). Specificity was verified in synthetic mixtures, and statistical comparison with a reference method confirmed equivalence. The green profile was affirmed by multiple sustainability assessment tools.

Conclusion

The proposed UV-Vis spectrophotometric method is simple, selective, accurate, precise, and environmentally friendly. Its validated performance and sustainability profile make it highly suitable for routine quality control of PG and DL in pharmaceutical analysis.

Keywords

Duloxtine
Ninhydrin
Pregabalin
Primary amine
Rheuman’s purple

1. INTRODUCTION

The concurrent use of pregabalin (PG) and duloxetine hydrochloride (DL) has become a clinically valuable regimen for managing diabetic peripheral neuropathy, owing to their complementary mechanisms of action.[14] PG, a γ-aminobutyric acid (GABA) analog [Figure 1a], modulates voltage-gated calcium channels, reducing the release of excitatory neurotransmitters like glutamate and substance P.[5] DL, a serotonin-norepinephrine reuptake inhibitor (SNRI) [Figure 1b], enhances monoaminergic transmission, contributing to both analgesia and mood stabilisation.[68] This synergistic effect improves pain scores and patient well-being, increasing the need for reliable analytical methods to quantify both drugs in combination products.

Chemical structures of (a) Pregabalin and (b) Duloxetine HCl.
Figure 1:
Chemical structures of (a) Pregabalin and (b) Duloxetine HCl.

Spectrophotometry is a fundamental technique in pharmaceutical analysis due to its simplicity, low cost, and minimal sample preparation.[9] However, its utility is limited for non-chromophoric compounds like PG, which lacks aromatic rings and exhibits only weak UV absorbance below 210 nm—rendering direct spectrophotometric analysis impractical and prone to interference from solvents and excipients. In contrast, DL possesses a conjugated naphthalene ring that allows direct UV detection at 230 nm.[10]

To overcome PG’s analytical challenge, derivatisation with chromogenic reagents offers a viable solution. Ninhydrin, a classical reagent for primary amines, reacts selectively with the aliphatic amine group of PG to form a stable, intensely coloured adduct known as Ruhemann’s purple, with a maximum absorbance at 570–580 nm.[11] This reaction, well-established in amino acid analysis, proceeds via nucleophilic attack of the primary amine on ninhydrin, forming an aldimine intermediate that condenses with a second ninhydrin molecule to yield the chromophore. The reaction efficiency depends on solvent, temperature, pH, and reagent concentration, all of which must be optimised for quantitative conversion.

Several ninhydrin-based methods exist for the individual determination of PG in bulk or dosage forms, often using solvents like dimethyl sulfoxide (DMSO) or aqueous buffers.[12,13] However, none have been developed for the simultaneous quantification of PG and DL in binary mixtures. While High Performance Liquid Chromatography (HPLC) methods offer high sensitivity and selectivity, they require expensive instrumentation and technical expertise, limiting their use in resource-constrained settings.

This work presents the first validated Ultraviolet-Visible (UV-Vis) spectrophotometric method for the simultaneous determination of PG and DL in synthetic mixtures. By derivatising PG with ninhydrin to form a visible-range chromophore (λmax = 580 nm) and directly assaying DL at 230 nm, the method exploits non-overlapping spectra to eliminate interference. The approach avoids complex mathematical treatments or physical separation. Fully validated per International Council for Harmonisation (ICH) Q2(R1) guidelines,[14] this strategy offers a simple, cost-effective, and environmentally benign alternative for routine quality control of this therapeutically significant combination.

2. MATERIAL AND METHODS

2.1. Instrumentation

All absorbance measurements were performed using a Shimadzu UV-1900i PC double-beam UV-Visible spectrophotometer (Shimadzu Corporation, Japan), equipped with 1.0 cm path length quartz cuvettes. Spectral data were acquired and processed using Labsolutions UV-VIS software. A JENWAY pH metre model 3510 (Cole-Parmer, UK) was used for pH measurements when required. Sample dissolution and homogenization were facilitated by an ultrasonic bath (FALC Instruments, Italy). An analytical balance (Vibra HT analytical balance, Japan) with a precision of ±0.01 mg was used for accurate weighing of standards and reagents.

2.2. Chemicals and reagents

PG and DL hydrochloride (purity >99.8%) were obtained as gift samples from EVA PHARM (Cairo, Egypt) and were used as reference standards. Certificate-verified purities were 99.92% for PG and 99.80% for DL. Ninhydrin (purity 99.86%) was purchased from Loba Chemie Pvt. Ltd. (Mumbai, India). Methanol (HPLC grade) was acquired from Fisher Scientific (UK). All other chemicals and solvents were of analytical reagent grade. Freshly double-distilled water was used throughout the study for the preparation of all aqueous solutions and dilutions.

2.3. Preparation of standard solutions

Stock solutions (1000 µg/mL): Accurately weighed quantities of PG (50.0 mg) and DL (50.0 mg) were separately transferred into 50 mL volumetric flasks. Each compound was dissolved in approximately 25 mL of methanol, followed by sonication for 5 minutes to ensure complete solubilisation. The solutions were then diluted to the mark with methanol, resulting in stock solutions of 1000 µg/mL (1.0 mg/mL) for each drug. These stock solutions were stable for at least one week when stored in amber glass bottles at 4°C.

Working standard solutions (100 µg/mL): Aliquots of 1.0 mL from each stock solution were transferred into separate 10 mL volumetric flasks and diluted to volume with methanol to obtain working standard solutions of 100 µg/mL for both PG and DL. These dilutions were used for the preparation of calibration standards and synthetic mixtures.

Synthetic binary mixtures: To evaluate the accuracy, specificity, and applicability of the method for simultaneous analysis, synthetic binary mixtures of PG and DL were prepared in methanol at various concentration ratios within the linear range of the assay (e.g., 1:1, 1:2, 2:1). These laboratory-prepared mixtures simulated potential pharmaceutical combinations and were used to assess the absence of mutual interference between the two analytes under the developed analytical conditions.

2.4. Procedures

The development of the simultaneous spectrophotometric method for PG and DL was based on a dual-detection strategy that exploits the complementary spectroscopic behaviour of the two drugs. The fundamental principle involves the indirect quantification of PG through a chromogenic derivatisation reaction with ninhydrin, while DL is determined directly via its intrinsic UV absorbance, thereby enabling their concurrent analysis without physical or mathematical separation.

2.4.1. Spectral characterisation and wavelength selection

Prior to method development, the zero-order UV absorption spectra of both drugs were recorded over the range of 200–400 nm using a methanol blank as reference. PG exhibited weak and poorly defined absorbance in the UV region, with a maximum near 210 nm, which is not suitable for selective quantification due to potential interference from solvents and excipients. In contrast, DL displayed a sharp and intense absorption peak at 230 nm, attributed to its conjugated naphthalene ring system, allowing for direct and reliable UV detection. To overcome the spectroscopic limitations of PG, a derivatisation approach was employed using ninhydrin, a well-known chromogenic reagent for primary amines. The reaction between PG and ninhydrin yielded a stable purple-coloured adduct, Ruhemann’s purple, which exhibited a distinct maximum absorbance at 580 nm in the visible region. This significant spectral separation, between the derivatised PG at 580 nm and undervatized DL at 230 nm, ensured the absence of mutual interference and formed the basis for the simultaneous determination of both analytes.

2.4.2. Derivatisation of pregabalin

The derivatisation procedure was optimised ensure complete and reproducible formation of the chromophoric complex. A 3% (w/v) solution of ninhydrin was freshly prepared in absolute ethanol and used as the derivatising agent. For the reaction, 1.0 mL of the PG working standard solution (100 µg/mL) was transferred into a 10 mL volumetric flask, followed by the addition of 1.0 mL of the 3% ninhydrin solution. The mixture was vortexed thoroughly to ensure homogeneity and then incubated in a thermoblock at 100°C for exactly 5 minutes to accelerate the condensation reaction. After heating, the flask was cooled to ambient temperature, and the solution was diluted to the mark with ethanol. A deep purple colour developed immediately, indicating the formation of the Ruhemann’s purple complex. The resulting solution was stable for at least 2 hours under room light, allowing sufficient time for spectrophotometric measurement.

2.4.3. Simultaneous quantification of pregabalin and duloxetine

For the simultaneous assay of both drugs in binary mixtures, a unified procedure was established. Aliquots of the working standard solutions of PG and DL were mixed in appropriate volumes to prepare calibration standards covering the concentration ranges of 3–30 µg/mL for PG and 1–35 µg/mL for DL. For each standard or sample, the derivatisation step was applied selectively to PG: 1.0 mL of the mixture was transferred to a 10 mL volumetric flask, 1.0 mL of 3% ethanolic ninhydrin was added, and the solution was processed as described above. The absorbance of the resulting solution was measured at two wavelengths: 580 nm, corresponding to the derivatisation PG complex, and 230 nm, corresponding to the native DL. The absorbance values were recorded against appropriate reagent blanks prepared in parallel. Calibration curves were constructed by plotting absorbance versus concentration for each drug independently. The concentration of PG was determined from the 580 nm plot, while that of DL was calculated from the 230 nm data. The method’s design ensures that the presence of DL does not interfere with the derivatization or detection of PG, and vice versa, due to the non-overlapping absorption maxima and the specificity of the ninhydrin reaction toward the primary aliphatic amine group of PG.

2.4.4. Greenness assessment

The proposed method environmental sustainability was assessed using four complementary greenness assessment tools: AGREE, GAPI, NEMI, and BAGI. The AGREE calculator (v.0.9.0) was applied to score compliance with the 10 principles of Green Analytical Chemistry, yielding a numerical value between 0 and 1. The GAPI pictogram was constructed by evaluating environmental impact across five analytical stages; sample collection, preparation, reagents, instrumentation, and waste, by using colour coding (green = low impact, yellow = medium, red = high). The NEMI pictogram was produced by four regulatory criteria evaluation: presence of Persistent, Bioaccumulative, and Toxic (PBT) substances, Resource Conservation and Recovery Act (RCRA)-listed hazardous waste, corrosive conditions (pH ≤ 2 or ≥ 12.5), and waste amount ≥50 g per analysis. Finally, the Bioanalytical Greenness Index (BAGI) was utilised to assign a domain-specific sustainability score (0–100) based on pharmaceutical analysis criteria, including sample volume, energy use, reagent hazard, and need for preconcentration. Additionally, the Eco-Scale metric was applied by assigning penalty points according to the reagents, energy consumption, waste generation, and operator safety, with the final score calculated as 100 minus the total penalty.

3. RESULTS AND DISCUSSION

3.1. Spectral characteristics

The analytical challenge in the simultaneous determination of PG and DL arises from their fundamentally different molecular architectures and, consequently, their different spectroscopic behaviours. PG, chemically known as (S)-3-(aminomethyl)-5-methylhexanoic acid, is a lipophilic analog of γ-aminobutyric acid (GABA) that lacks aromatic rings or extended conjugated π-systems. As a result, its electronic transitions occur primarily in the far-UV region, where absorbance is weak, poorly resolved, and highly interfered with by common solvents and excipients [Figure 2]. This absence of a strong chromophore renders direct UV-Vis spectrophotometric quantification impractical, particularly in multi-component systems such as fixed-dose combinations or biological matrices where overlapping signals can compromise selectivity and accuracy.

Zero-order UV absorption spectrum of pregabalin in methanol (a) before and (b) after ninhydrin derivatisation. (c) Overlayed different concentrations of pregabalin-ninhydrin complex and Duloxetine HCl at different concentrations. The colour-coded curves represent the absorbance spectra of the pregabalin-ninhydrin complex at different concentrations. The colors correspond to increasing concentration levels, as follows: Highest concentration (Violet): 30 µg/mL, Red: 25 µg/mL, Black: 20 µg/mL, Blue: 15 µg/mL, Orange: 10 µg/mL, Blue: Lowest concentration (5 µg/mL), The increasing absorbance intensity with concentration demonstrates the method’s linearity and sensitivity for quantitative analysis.
Figure 2:
Zero-order UV absorption spectrum of pregabalin in methanol (a) before and (b) after ninhydrin derivatisation. (c) Overlayed different concentrations of pregabalin-ninhydrin complex and Duloxetine HCl at different concentrations. The colour-coded curves represent the absorbance spectra of the pregabalin-ninhydrin complex at different concentrations. The colors correspond to increasing concentration levels, as follows: Highest concentration (Violet): 30 µg/mL, Red: 25 µg/mL, Black: 20 µg/mL, Blue: 15 µg/mL, Orange: 10 µg/mL, Blue: Lowest concentration (5 µg/mL), The increasing absorbance intensity with concentration demonstrates the method’s linearity and sensitivity for quantitative analysis.

In contrast, DL (±)-N-methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl) propan-1-amine, contains a naphthalene ring, a polycyclic aromatic hydrocarbon, that serves as a robust chromophore due to its extended π-conjugation. This structural feature enables DL to exhibit a well-defined and intense absorption maximum at 230 nm, allowing for direct and reliable quantification via UV spectrophotometry without the need for chemical modification. The difference in detectability between the two drugs, where one is non-chromophoric and the other is inherently UV-active, presents both a challenge and an opportunity. The challenge lies in enabling the simultaneous analysis of both drugs without cross-interference, while the opportunity arises from exploiting this fundamental difference through a selective derivatisation strategy that targets only one component of the mixture. To bridge this analytical gap, a chemical derivatisation strategy was employed to enhance the detectability of PG. The key functional group targeted in this approach is the primary aliphatic amine located at the 3-aminomethyl position of PG. This primary amine is highly reactive toward ninhydrin (2,2-dihydroxy-1,3-indanedione), a classical chromogenic reagent extensively used in amino acid and amine analysis. The reaction between ninhydrin and primary amines is one of the most well-characterised transformations in analytical organic chemistry and forms the basis of the ninhydrin test, a standard qualitative and quantitative assay for α-amino acids and primary amines.[15]

The reaction proceeds through a multi-step mechanism that begins with the nucleophilic attack of the primary amine of PG on one of the carbonyl groups of ninhydrin, forming a Schiff base (aldimine) intermediate. This step is followed by decarboxylation (in the case of α-amino acids) or direct dehydration (in the case of primary amines like PG), leading to the formation of a reduced ninhydrin species (dihydroruhemann’s purple) and an imine derivative. A second molecule of ninhydrin then condenses with this intermediate to yield the final product: Ruhemann’s purple (diketohydrindylidene-diketohydrindamine), a deeply coloured, resonance-stabilised quinoidal compound with a characteristic absorption maximum at 580 nm in the visible region.[16] This chromogenic transformation is highly specific for primary amines, which are less sterically hindered and more nucleophilic than secondary or tertiary amines. The reaction does not proceed with tertiary amines, and secondary amines yield a different, yellow-coloured product, which absorbs at a shorter wavelength and does not interfere with the detection of Ruhemann’s purple.[17] This selectivity ensures that only PG undergoes derivatisation, while DL, whose amine is tertiary (N-methyl group), remains unreacted and can be quantified directly at 230 nm. The complete spectral separation between the two detection wavelengths (580 nm for PG-N and 230 nm for DL) enables their simultaneous determination without the need for mathematical resolution, derivative spectroscopy, or physical separation techniques.

3.2. Method validation and statistical analysis

The proposed dual-detection method was rigourously validated according to the International Conference on Harmonisation (ICH) guidelines Q2(R1) to ensure its suitability for routine quality control applications. The validation parameters were evaluated for both PG and DL separately [Supplementary Table 1].

Supplementary Table 1

The linearity of the method was established over the concentration ranges of 3–30 µg/mL for PG [Figure 2b] and 1–35 µg/mL for DL [Figure 2c]. Calibration curves were constructed by plotting absorbance against concentration. The regression analysis yielded excellent correlation coefficients (r2) of 0.9996 for PG and 0.9997 for DL, indicating a strong linear relationship between the response and the analyte concentration within the specified ranges. The regression equations were determined as follows: For PG, Absorbance = 0.0371 C - 0.0068; for DL, Absorbance = 0.0207 C - 0.0138, where C is the concentration in µg/mL.

The accuracy of the method was assessed by performing recovery studies using the standard addition technique. Six different samples of each drug were prepared at three different concentrations and analysed in triplicate. The mean percentage recovery for PG was 100.57 ± 1.16%, while for DL, it was 100.58 ± 1.26%. These results confirm the high accuracy of the method, with recoveries falling within the acceptable range of 98–102%. The method’s precision was evaluated in terms of repeatability (intra-day precision) and intermediate precision (inter-day precision). Repeatability was determined by analysing six samples of each drug at three concentrations on the same day, yielding % RSD values of 1.15% for PG and 1.18% for DL. Intermediate precision was assessed by analysing the same samples on three successive days, resulting in % RSD values of 1.0742% for PG and 1.045% for DL. These low % RSD values demonstrate the high reproducibility and reliability of the method.

Specificity was confirmed by analysing a mixture of the two drugs, which showed no interference between the components, as evidenced by the distinct absorbance maxima at 580 nm for the derivatised PG complex and 230 nm for the native DL.

The LOD and LOQ were calculated using the formulae LOD = 3.3 × S.D./Slope and LOQ = 10 × S.D./Slope, respectively, where S.D. is the standard deviation of the response and Slope is the slope of the calibration curve. The LOD values were determined to be 0.5489 µg/mL for PG and 0.2425 µg/mL for DL. The LOQ values were 1.6633 µg/mL for PG and 0.7349 µg/mL for DL. These low limits of detection and quantitation indicate the high sensitivity of the method.

The method was further validated by applying it to laboratory-prepared mixtures containing different ratios of PG and DL [Supplementary Table 2]. The results demonstrated a mean percentage recovery of 100.34% for PG with a relative standard deviation (RSD) of 0.8794%, and a mean recovery of 99.7367% for DL with an RSD of 0.9538%. The low RSD values confirm the high precision of the method when applied to complex mixtures. The F-values for both drugs were significantly greater than the critical F-value at the 95% confidence level, indicating that the method is robust and reliable for the simultaneous determination of both drugs in binary mixtures.

Supplementary Table 2

3.3. Mechanistic and thermodynamic basis for optimisation of derivatisation conditions

The efficiency, reproducibility, and sensitivity of the ninhydrin-based derivatisation are profoundly influenced by the reaction environment, including solvent, temperature, time, pH, and reagent concentration. A deep understanding of the underlying organic chemistry is essential for rational optimisation.

The reaction mechanism involves polar intermediates and proton transfer steps [Figure 3], making it highly sensitive to solvent polarity and protic character. The figure shows the mechanism of the nucleophilic attack of pregabalin’s primary amine on the electrophilic carbonyl carbon of ninhydrin, forming a Schiff’s base via condensation and loss of two water molecules. This intermediate undergoes decarboxylation, releasing CO₂ and rearranging into a stabilised iminium species. A subsequent condensation with a second ninhydrin molecule, followed by elimination of water and 2-methylpentane-2,4-dione, yields the final Ruhemann’s purple chromophore. Each step involves transient polar species and proton transfer, which are strongly influenced by the solvent’s ability to donate and accept hydrogen bonds.[18] Among the solvents evaluated, methanol, ethanol, acetonitrile, and water, ethanol emerged as the optimal medium. As a polar protic solvent, ethanol effectively solvates both ninhydrin and PG, facilitates proton transfer during condensation, and stabilises charged intermediates. It also enhances chromophore solubility, preventing precipitation and ensuring a homogeneous solution for accurate absorbance measurement. In contrast, aqueous media produced lower colour intensity due to limited ninhydrin solubility and potential reagent hydrolysis. Aprotic solvents like acetonitrile failed to support efficient reaction kinetics, underscoring the necessity of a protic environment for successful transformation.

The proposed mechanism of complex reaction of pregabalin and Ninhydrin.
Figure 3:
The proposed mechanism of complex reaction of pregabalin and Ninhydrin.

The concentration of ninhydrin was optimised to ensure stoichiometric excess for complete conversion of PG while minimising reagent waste and background absorbance. A 3% (w/v) ethanolic solution was found to be optimal. Lower concentrations led to incomplete derivatisation, as evidenced by sub-maximal absorbance, while higher concentrations did not enhance the signal and increased the risk of side reactions or reagent aggregation. This concentration aligns with those reported in classical methods for amino acid analysis, where a 2–4% ninhydrin solution is typically used to ensure quantitative reaction.[19]

Temperature and reaction time are critical kinetic parameters. The formation of Ruhemann’s purple is an endothermic process that requires thermal activation to overcome the energy barrier for imine formation and subsequent condensation. Incubation at 100°C for 5 minutes was sufficient to achieve complete chromophore formation, as confirmed by a plateau in absorbance values. Prolonged heating beyond this point did not increase the signal and, in some cases, led to a slight decrease in absorbance, suggesting possible degradation of the chromophore or oxidative side reactions. The use of a thermoblock ensured uniform and reproducible heating, minimising variability between samples.

The pH of the reaction medium also plays a crucial role, although in this case, the reaction was carried out in ethanol without explicit pH adjustment. In aqueous systems, the ninhydrin reaction is known to proceed optimally under slightly acidic to neutral conditions (pH 5–7), where the amine is sufficiently nucleophilic (as the free base) while the carbonyl groups of ninhydrin remain electrophilic. In strongly acidic media, the amine is protonated and thus less nucleophilic, slowing the reaction. In strongly alkaline conditions, ninhydrin may undergo hydrolysis or side reactions. The use of ethanol as a solvent effectively buffers these effects, providing a neutral, non-aqueous environment conducive to the reaction.

3.4. Quantitative greenness outcomes and sustainability interpretation

The greenness assessment yielded quantitatively favourable outcomes across all four tools [Table 1]. The AGREE calculator returned a score of 0.75, derived from 12 criteria: 8 scored green (waste <10 mL/sample; energy = 5 min at 100°C + UV-Vis; ethanol as renewable solvent; no PBT reagents; simple sample prep; high throughput; biodegradable waste; operator safety under standard lab conditions), while 2 scored yellow (no real-time monitoring; manual operation), and one scored red. The GAPI pictogram showed five green segments, justified as follows: (1) sample collection involved solid tablets (no biohazard); (2) sample preparation required only 1 mL methanol dissolution + 1 mL 3% (w/v) ninhydrin in ethanol, with no extraction or cleanup; (3) reagents included ethanol (Class 3 solvent, ICH Q3C), ninhydrin (0.03 g per sample), and trace methanol (1 mL, Class 2); (4) instrumentation used a low-power UV-Vis spectrophotometer (<100 W); and (5) total waste was 8.3 g/sample (6.3 g ethanol + 0.8 g methanol + 0.03 g ninhydrin + 1.2 g water-equivalent), all biodegradable. The NEMI pictogram was fully white because: (i) no PBT substances were used (CAS 485-47-2 for ninhydrin is not PBT); (ii) no RCRA-listed waste was generated; (iii) reaction pH was neutral (∼7 in ethanol); and (iv) waste mass (8.3 g) was <17% of the 50 g threshold. Finally, the BAGI tool assigned a score of 82.5/100, calculated from: sample volume = 1 mL (max 5 mL allowed), preconcentration = not required, reagent hazard = low (ethanol dominant), energy = low (5 min heating), and instrumentation = non-hazardous. Complementing these results, the method achieved an excellent Eco-Scale score of 92, reflecting a total penalty of only 8 points assigned according to the reagent hazard, energy use, waste generation, and operator safety. Collectively, these metrics confirm the method’s high sustainability, with <10 mL solvent consumption, <9 g waste, and zero use of halogenated or persistent chemicals.

Table 1: Greenness of the proposed method using AGREE, GAPI, NEMI, Eco-scale and BAGI assessment tools.
Eco-scale assessment tools
Reagents parameter Penalty points

Ethanol (solvent and diluent)

Methanol (sample dissolution)

Ninhydrin (3% w/v solution)

Energy consumption

Waste generated

Operator safety

1

2

1

1

2

1

Total penalty

Score

8

92

AGREE GAPI NEMI BAGI

4. CONCLUSION

This study presents a validated, derivatisation based spectrophotometric method for the simultaneous quantification of PG and duloxetine. By converting non-chromophoric pregabalin into a visible light-absorbing complex using ninhydrin and directly assaying duloxetine in the UV range, accurate and interference-free analysis was achieved. The method is linear, accurate, precise, and sensitive, fully complying with ICH validation guidelines. Its simplicity, low cost, and minimal environmental impact make it ideal for routine pharmaceutical quality control, especially in resource limited settings. This work highlights the enduring value of classical colourimetric strategies in solving modern analytical challenges. The method’s sustainability was objectively confirmed through comprehensive greenness assessment using AGREE, GAPI, NEMI, Eco-Scale and BAGI tools.

Ethical approval

Institutional Review Board (IRB) approval is not required for this study, as it involved only in vitro analysis of commercially available pharmaceutical formulations and spiked laboratory-prepared plasma samples. No human subjects were involved in data collection, and no clinical trials were conducted.

Declaration of patient consent

Patient consent is not applicable. The study did not involve direct interaction with patients, and the plasma samples used were anonymised residual material obtained from a hospital biobank for method validation purposes, under an existing institutional protocol that does not require individual consent.

Financial support and sponsorship

Nil

Conflicts of interest

Dr. Ali Yehia is on the Editorial Board of the Journal.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

References

  1. , et al. The Journal of Pain. 2005;6:253-260.
    [CrossRef] [PubMed]
  2. , et al. BMC Neurology. 2008;8:29.
    [CrossRef] [PubMed] [PubMed Central]
  3. , et al. Diabetes Therapy. 2019;10:35-56.
    [CrossRef] [PubMed] [PubMed Central]
  4. , et al. Mayo Clinic Proceedings. 2011;86:615-626.
    [CrossRef] [PubMed] [PubMed Central]
  5. , et al. Drugs. 2005;65:111-118.
    [CrossRef] [PubMed]
  6. , et al. Psychopharmacology Bulletin. 2002;36:106-132.
    [PubMed]
  7. , et al. CNS Drug Reviews. 2002;8:361-376.
    [CrossRef] [PubMed] [PubMed Central]
  8. , et al. CNS Drugs. 2009;23:523-541.
    [CrossRef] [PubMed]
  9. , et al. Cengage Learning. 2019;6:475.
  10. , et al. International Journal of Pharmacy and Pharmaceutical Sciences. 2019;11:27-31.
  11. , et al. Journal of Agricultural and Food Chemistry. 2004;52:385-406.
    [CrossRef] [PubMed]
  12. , et al. Journal of Chromatography B. 2014;962:82-88.
  13. , et al. Critical Reviews in Analytical Chemistry. 2022;52:1048-1068.
    [CrossRef] [PubMed]
  14. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2005). Validation of analytical procedures: Text and methodology Q2(R1). [Last accessed date: 15 July 2025]. Available from: https://database.ich.org/sites/default/files/Q2-R1_Guideline.pdf
  15. , et al. Advances in Protein Chemistry. 1945;2:1-83.
  16. , et al. Analytical Biochemistry. 1988;174:1-16.
    [CrossRef] [PubMed]
  17. , et al. Analytical Chemistry. 1949;21:1249-1266.
  18. , et al. Longmans. 1956;2:676-681.
  19. , et al. Journal of Biological Chemistry. 1985;260:7094-7101.
    [PubMed]
Show Sections